Trials / Completed
CompletedNCT00516802
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
| DRUG | dacarbazine | intravenous injection over at least 20 minutes |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2007-08-15
- Last updated
- 2009-05-15
Locations
4 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00516802. Inclusion in this directory is not an endorsement.